Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that familiar routine of calls and deadlines has predictably returned. But what can you do? After all, the world keeps spinning. On that note, we will give it a nudge by brewing another cup of stimulation. Our choice today is caramel salted mocha — a touch of the Jersey Shore. Meanwhile, here are a few items of interest to get you going. Hope your day goes well and, of course, do stay in touch. …

Emergent BioSolutions (EBS) chief executive officer Robert Kramer sold more than $10 million worth of his stock in the company in January and early February, just weeks before the disclosure that production problems at its Baltimore plant had ruined 15 million doses of the Johnson & Johnson (JNJ) Covid-19 vaccine, The Washington Post reports. Reports of the contamination came after Emergent shares had tumbled on Feb. 19, following the company’s published financial results.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What’s included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.


Leave a Reply

ArabicChinese (Simplified)EnglishFrenchGermanItalianJapanesePortugueseRussianSpanish

[mc4wp_form id="449"]